Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)

doi: 10.1111/ene.13594.

Multiple Sclerosis

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

PLoS One.

Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G

doi: 10.1371/

Multiple Sclerosis

Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Mult Scler.

Wiendl H, Spelman T, Butzkueven H, Kappos L, Trojano M, Su R, Campbell N, Ho PR, Licata S

doi: 10.1177/1352458520926869.

Multiple Sclerosis

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis

Expert Opin Drug Saf.

Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L

doi: 10.1080/14740338.

Multiple Sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Brain.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M

doi: 10.1093/brain/awx250.

RECOMMENDED

Aging and Cognitive FunctionsMultiple Sclerosis

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis

Brain.

Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O

doi: 10.1093/brain/awz156.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Mult Scler.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö

doi: 10.1177/1352458518768433.

Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Mult Scler.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P

doi: 10.1177/1352458519881759.

Related content

Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis

Vaccination Readiness in Multiple Sclerosis

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies